Passa al contenuto
Merck

Porcine iPSC Generation: Testing Different Protocols to a Successful Application.

Methods in molecular biology (Clifton, N.J.) (2021-12-01)
Oriol Iborra-Egea, Daina Martínez-Falguera, Santiago Roura, Antoni Bayes-Genis, Ángel Raya, Carolina Gálvez-Montón
ABSTRACT

Stem cell therapy has an unparalleled potential to treat blood cancers, cardiovascular diseases and neurodegenerative conditions, among others. However, stem cell therapeutics must overcome multiple requirements before reaching clinical trials, including large animal safety and efficacy studies. In cardiovascular diseases swine models are the most widely adopted due to its great translational potential to humans. In this chapter, we will describe several protocols to induce iPSC dedifferentiation in swine fibroblasts, as well as conditioning treatments that may help in the reprogramming process.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
CHIR99021, ≥98% (HPLC)
Sigma-Aldrich
hBFGF, FGF-Basic, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Puromicina, Ready Made Solution, from Streptomyces alboniger, 10 mg/mL in H2O, suitable for cell culture
Sigma-Aldrich
Proteina LIF ricombinante di topo ESGRO®, ESGRO Leukemia Inhibitory Factor (LIF) supplement for mouse ES cell culture. Each vial contains 10^7 units/ml.
Sigma-Aldrich
SB 431542, ≥98% (HPLC), powder
Roche
Sieroalbumina bovina, blood typing: suitable, Endonuclease, Exonuclease, Rnases, Proteinases free
Sigma-Aldrich
5-Aza-2′-deoxycytidine, ≥97%
Sigma-Aldrich
MEK1/2 Inhibitor III, The MEK1/2 Inhibitor III, also referenced under CAS 391210-10-9, controls the biological activity of MEK1/2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.